de St Maurice Annabelle M, Bridges Brian C, Rycus Peter T, Fonnesbeck Christopher J, Fleming Geoffrey M, Halasa Natasha B
1Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, TN. 2Extracorporeal Life Support Organization, University of Michigan, Ann Arbor, MI. 3Department of Biostatistics, Vanderbilt University School of Medicine, Nashville, TN.
Pediatr Crit Care Med. 2016 Sep;17(9):876-83. doi: 10.1097/PCC.0000000000000843.
To determine the overall use of extracorporeal membranous oxygenation for influenza-associated illness and describe risk factors associated with mortality in these patients.
Retrospective multicenter cohort analysis.
The international Extracorporeal Life Support Organization database was queried for patients with influenza-associated illness on extracorporeal membranous oxygenation from 1992 to 2014.
In total, 1,654 patients with influenza-associated illness on extracorporeal membranous oxygenation.
None.
Demographic and clinical data collected included age, type of support, duration of support, type of microbial codetection, complications, and survival status at discharge. The primary outcome of interest was survival to hospital discharge. From 1992 to 2014, 1,688 (3%) of the 61,336 extracorporeal membranous oxygenation runs were due to influenza-associated illness reflecting 1,654 unique patients: 30 (2%) were neonates, 521 (31%) were pediatric patients, and 1,103 (67%) were adults. Extracorporeal membranous oxygenation use for influenza-associated illness increased from 1992 to 2014, with a marked increase in use after the 2009 H1N1 pandemic. Survival to hospital discharge of patients with influenza-associated illness on extracorporeal membranous oxygenation was 63% and was not affected by bacterial codetection. However, when patients with Staphylococcus aureus codetection were compared with those with another bacterial codetection, their survival to hospital discharge was significantly lower (52% vs 67%; p < 0.01). In a logistic regression model, the effect of S. aureus on in-hospital mortality varied by age group, with younger patients with S. aureus having increased in-hospital mortality.
Extracorporeal membranous oxygenation use for individuals with influenza increased over time, particularly after the 2009 H1N1 pandemic, most notably among older adults. Survival to hospital discharge for patients with influenza on extracorporeal membranous oxygenation was slightly higher than survival to hospital discharge for respiratory illness due to any cause. Bacterial codetection was common among patients with influenza on extracorporeal membranous oxygenation and was associated with increased days on extracorporeal membranous oxygenation but not increased mortality. Only S. aureus codetection in children was associated with increased in-hospital mortality.
确定体外膜肺氧合在流感相关疾病中的总体应用情况,并描述这些患者死亡的相关危险因素。
回顾性多中心队列分析。
查询国际体外生命支持组织数据库中1992年至2014年接受体外膜肺氧合治疗的流感相关疾病患者。
共有1654例接受体外膜肺氧合治疗的流感相关疾病患者。
无。
收集的人口统计学和临床数据包括年龄、支持类型、支持持续时间、微生物共检测类型、并发症及出院时的生存状态。主要关注的结局是出院存活。1992年至2014年,61336例体外膜肺氧合治疗中有1688例(3%)是因流感相关疾病,涉及1654例不同患者:30例(2%)为新生儿,521例(31%)为儿科患者,1103例(67%)为成人。1992年至2014年,体外膜肺氧合在流感相关疾病中的应用有所增加,2009年甲型H1N1流感大流行后使用量显著增加。接受体外膜肺氧合治疗的流感相关疾病患者出院存活率为63%,不受细菌共检测的影响。然而,将检测到金黄色葡萄球菌的患者与检测到其他细菌的患者进行比较时,前者出院存活率显著较低(52%对67%;p<0.01)。在逻辑回归模型中,金黄色葡萄球菌对住院死亡率的影响因年龄组而异,感染金黄色葡萄球菌的年轻患者住院死亡率增加。
随着时间推移,体外膜肺氧合在流感患者中的应用增加,尤其是在2009年甲型H1N1流感大流行之后,在老年人中最为显著。接受体外膜肺氧合治疗的流感患者出院存活率略高于因任何原因导致的呼吸系统疾病患者出院存活率。体外膜肺氧合治疗的流感患者中细菌共检测很常见,与体外膜肺氧合治疗天数增加有关,但与死亡率增加无关。仅儿童检测到金黄色葡萄球菌与住院死亡率增加有关。